Alnylam

Press Releases

Feb 05,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming February Investor Conferences
PDF Version
Feb 01,2018
Summary ToggleAlnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
PDF Version
Feb 01,2018
Summary ToggleAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results
PDF Version
Jan 25,2018
Summary ToggleAlnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
PDF Version
Jan 07,2018
Summary ToggleAlnylam Announces 2018 Corporate Goals
PDF Version
Jan 07,2018
Summary ToggleAlnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
PDF Version
Jan 04,2018
Summary ToggleAlnylam Expands Alnylam Act™ Program to Include No-Charge Third-Party Genetic Testing and Counseling for People at Risk for Acute Hepatic Porphyrias
PDF Version
Jan 02,2018
Summary ToggleAlnylam to Webcast Presentation at 36th Annual J.P. Morgan Healthcare Conference
PDF Version
Dec 28,2017
Summary ToggleAlnylam to Webcast Presentation at Goldman Sachs Healthcare CEOs Unscripted Conference
PDF Version
Dec 18,2017
Summary ToggleAlnylam and Sanofi Submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
PDF Version
Dec 15,2017
Summary ToggleFDA Lifts Clinical Hold on Fitusiran
PDF Version
Dec 12,2017
Summary ToggleAlnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
PDF Version
Dec 11,2017
Summary ToggleAlnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis
PDF Version
Dec 07,2017
Summary ToggleAlnylam to Webcast Presentation at BMO Capital Markets Prescriptions for Success Healthcare Conference
PDF Version
Nov 20,2017
Summary ToggleU.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy
PDF Version
Nov 16,2017
Summary ToggleAlnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PDF Version
Nov 16,2017
Summary ToggleAlnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
PDF Version
Nov 13,2017
Summary ToggleAlnylam Pharmaceuticals Prices Public Offering of Common Stock
PDF Version
Nov 13,2017
Summary ToggleEuropean Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis
PDF Version
Nov 13,2017
Summary ToggleAlnylam Pharmaceuticals Announces Proposed Public Offering of $675,000,000 of Common Stock
PDF Version
Displaying 21 - 40 of 951 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More